The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council

Detalles Bibliográficos
Autores principales: Agboola, Foluso, Rind, David M, Walton, Surrey M, Herron-Smith, Serina, Quach, Danny, Pearson, Steven D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Perspectives on Value
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390946/
https://www.ncbi.nlm.nih.gov/pubmed/33908280
http://dx.doi.org/10.18553/jmcp.2021.27.5.667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390946/
https://www.ncbi.nlm.nih.gov/pubmed/33908280
http://dx.doi.org/10.18553/jmcp.2021.27.5.667

Ejemplares similares